These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Challenges and prospects of immunotherapy as cancer treatment. Rescigno M; Avogadri F; Curigliano G Biochim Biophys Acta; 2007 Sep; 1776(1):108-23. PubMed ID: 17720322 [TBL] [Abstract][Full Text] [Related]
25. Cancer immunotherapy: Breakthrough or "deja vu, all over again"? Sell S Tumour Biol; 2017 Jun; 39(6):1010428317707764. PubMed ID: 28639883 [TBL] [Abstract][Full Text] [Related]
26. [The Pedigree of Immuno-Oncology - History and Current Status of Immunotherapy against Malignancy]. Sugiyama Y Gan To Kagaku Ryoho; 2018 Sep; 45(9):1228-1233. PubMed ID: 30237360 [TBL] [Abstract][Full Text] [Related]
27. Cancer vaccines: what do we need to measure in clinical trials? Kudrin A Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508 [TBL] [Abstract][Full Text] [Related]
28. Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated Hernández-Luna MA; Luria-Pérez R J Immunol Res; 2018; 2018():2984247. PubMed ID: 30302344 [TBL] [Abstract][Full Text] [Related]
32. Cancer Neoantigens and Applications for Immunotherapy. Desrichard A; Snyder A; Chan TA Clin Cancer Res; 2016 Feb; 22(4):807-12. PubMed ID: 26515495 [TBL] [Abstract][Full Text] [Related]
33. The potential of nanoparticle vaccines as a treatment for cancer. Urbanavicius D; Alvarez T; Such GK; Johnston APR; Mintern JD Mol Immunol; 2018 Jun; 98():2-7. PubMed ID: 29395251 [TBL] [Abstract][Full Text] [Related]
34. Immunotherapy of tumors with vaccines based on xenogeneic homologous molecules. Wei YQ Anticancer Drugs; 2002 Mar; 13(3):229-35. PubMed ID: 11984066 [TBL] [Abstract][Full Text] [Related]
35. Immunotherapy advances in uro-genital malignancies. Ratta R; Zappasodi R; Raggi D; Grassi P; Verzoni E; Necchi A; Di Nicola M; Salvioni R; de Braud F; Procopio G Crit Rev Oncol Hematol; 2016 Sep; 105():52-64. PubMed ID: 27372200 [TBL] [Abstract][Full Text] [Related]
36. A review of dendritic cell therapy for cancer: progress and challenges. Mantia-Smaldone GM; Chu CS BioDrugs; 2013 Oct; 27(5):453-68. PubMed ID: 23592406 [TBL] [Abstract][Full Text] [Related]
37. Are peptide vaccines viable in combination with other cancer immunotherapies? Ohtake J; Sasada T Future Oncol; 2017 Aug; 13(18):1577-1580. PubMed ID: 28776424 [No Abstract] [Full Text] [Related]
38. [Immunotherapy of solid tumor: perspectives on vaccine and cell therapy]. Ikeda H; Shiku H Nihon Rinsho; 2012 Dec; 70(12):2043-50. PubMed ID: 23259373 [TBL] [Abstract][Full Text] [Related]
39. [NY-ESO-1 and cancer immunotherapy]. Peng JR; Leng XS Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604 [TBL] [Abstract][Full Text] [Related]
40. The growing evidence of the role of T-cells in the treatment of solid tumors. Kobayashi A; Pulitanò C; Liddo G; Ohkohchi N Ann Surg Oncol; 2008 Apr; 15(4):1254; author reply 1255. PubMed ID: 18165881 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]